Treatment of Frey's syndrome with botulinum toxin type B

Giovanna Cantarella, Alessandra Berlusconi, Vincenzo Mele, Filippo Cogiamanian, Sergio Barbieri

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective: Frey's syndrome is a frequent sequela of parotidectomy, causing facial sweating and flushing because of gustatory stimuli. Although botulinum toxin type A has become first-line therapy for Frey's syndrome, some patients become resistant. In this study, we investigated whether another serotype, botulinum toxin type B, might be an effective alternative. Study Design: Case series with planned data collection. Setting: Otolaryngology department in a university hospital. Subjects and Methods: Seven patients aged 30 to 68 years, with severe Frey's syndrome, underwent the Minor test and had 80 U of botulinum toxin type B per cm2 (mean total dose, 2354 U) injected intracutaneously in the mapped area of gustatory sweating. All patients were followed up for 12 months. Results: One month after treatment, six of the seven patients reported that gustatory sweating and flushing had resolved, and, in the remaining patient, these symptoms had decreased. The Minor test confirmed a significant improvement. The subjective benefits remained stable for six months in four patients and for nine months in the remaining three patients; 12 months after treatment, all patients still reported some improvement. Conclusion: Botulinum toxin type B afforded symptomatic relief in a small sample of patients with Frey's syndrome and might be considered a potential alternative to botulinum toxin type A.

Original languageEnglish
Pages (from-to)214-218
Number of pages5
JournalOtolaryngology - Head and Neck Surgery
Volume143
Issue number2
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Gustatory Sweating
Type A Botulinum Toxins
Therapeutics
rimabotulinumtoxinB
Sweating
Otolaryngology

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery
  • Medicine(all)

Cite this

Treatment of Frey's syndrome with botulinum toxin type B. / Cantarella, Giovanna; Berlusconi, Alessandra; Mele, Vincenzo; Cogiamanian, Filippo; Barbieri, Sergio.

In: Otolaryngology - Head and Neck Surgery, Vol. 143, No. 2, 08.2010, p. 214-218.

Research output: Contribution to journalArticle

@article{76ae39c40c004508b6e49c805fd1d126,
title = "Treatment of Frey's syndrome with botulinum toxin type B",
abstract = "Objective: Frey's syndrome is a frequent sequela of parotidectomy, causing facial sweating and flushing because of gustatory stimuli. Although botulinum toxin type A has become first-line therapy for Frey's syndrome, some patients become resistant. In this study, we investigated whether another serotype, botulinum toxin type B, might be an effective alternative. Study Design: Case series with planned data collection. Setting: Otolaryngology department in a university hospital. Subjects and Methods: Seven patients aged 30 to 68 years, with severe Frey's syndrome, underwent the Minor test and had 80 U of botulinum toxin type B per cm2 (mean total dose, 2354 U) injected intracutaneously in the mapped area of gustatory sweating. All patients were followed up for 12 months. Results: One month after treatment, six of the seven patients reported that gustatory sweating and flushing had resolved, and, in the remaining patient, these symptoms had decreased. The Minor test confirmed a significant improvement. The subjective benefits remained stable for six months in four patients and for nine months in the remaining three patients; 12 months after treatment, all patients still reported some improvement. Conclusion: Botulinum toxin type B afforded symptomatic relief in a small sample of patients with Frey's syndrome and might be considered a potential alternative to botulinum toxin type A.",
author = "Giovanna Cantarella and Alessandra Berlusconi and Vincenzo Mele and Filippo Cogiamanian and Sergio Barbieri",
year = "2010",
month = "8",
doi = "10.1016/j.otohns.2010.04.009",
language = "English",
volume = "143",
pages = "214--218",
journal = "Otolaryngology - Head and Neck Surgery",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment of Frey's syndrome with botulinum toxin type B

AU - Cantarella, Giovanna

AU - Berlusconi, Alessandra

AU - Mele, Vincenzo

AU - Cogiamanian, Filippo

AU - Barbieri, Sergio

PY - 2010/8

Y1 - 2010/8

N2 - Objective: Frey's syndrome is a frequent sequela of parotidectomy, causing facial sweating and flushing because of gustatory stimuli. Although botulinum toxin type A has become first-line therapy for Frey's syndrome, some patients become resistant. In this study, we investigated whether another serotype, botulinum toxin type B, might be an effective alternative. Study Design: Case series with planned data collection. Setting: Otolaryngology department in a university hospital. Subjects and Methods: Seven patients aged 30 to 68 years, with severe Frey's syndrome, underwent the Minor test and had 80 U of botulinum toxin type B per cm2 (mean total dose, 2354 U) injected intracutaneously in the mapped area of gustatory sweating. All patients were followed up for 12 months. Results: One month after treatment, six of the seven patients reported that gustatory sweating and flushing had resolved, and, in the remaining patient, these symptoms had decreased. The Minor test confirmed a significant improvement. The subjective benefits remained stable for six months in four patients and for nine months in the remaining three patients; 12 months after treatment, all patients still reported some improvement. Conclusion: Botulinum toxin type B afforded symptomatic relief in a small sample of patients with Frey's syndrome and might be considered a potential alternative to botulinum toxin type A.

AB - Objective: Frey's syndrome is a frequent sequela of parotidectomy, causing facial sweating and flushing because of gustatory stimuli. Although botulinum toxin type A has become first-line therapy for Frey's syndrome, some patients become resistant. In this study, we investigated whether another serotype, botulinum toxin type B, might be an effective alternative. Study Design: Case series with planned data collection. Setting: Otolaryngology department in a university hospital. Subjects and Methods: Seven patients aged 30 to 68 years, with severe Frey's syndrome, underwent the Minor test and had 80 U of botulinum toxin type B per cm2 (mean total dose, 2354 U) injected intracutaneously in the mapped area of gustatory sweating. All patients were followed up for 12 months. Results: One month after treatment, six of the seven patients reported that gustatory sweating and flushing had resolved, and, in the remaining patient, these symptoms had decreased. The Minor test confirmed a significant improvement. The subjective benefits remained stable for six months in four patients and for nine months in the remaining three patients; 12 months after treatment, all patients still reported some improvement. Conclusion: Botulinum toxin type B afforded symptomatic relief in a small sample of patients with Frey's syndrome and might be considered a potential alternative to botulinum toxin type A.

UR - http://www.scopus.com/inward/record.url?scp=77955494689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955494689&partnerID=8YFLogxK

U2 - 10.1016/j.otohns.2010.04.009

DO - 10.1016/j.otohns.2010.04.009

M3 - Article

VL - 143

SP - 214

EP - 218

JO - Otolaryngology - Head and Neck Surgery

JF - Otolaryngology - Head and Neck Surgery

SN - 0194-5998

IS - 2

ER -